rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ALEC
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Wells Fargo initiates Alector stock with overweight on Alzheimer’s drug potential
      Nov 13Investing.comALEC
      Are Medical Stocks Lagging Alector (ALEC) This Year?
      Nov 11Yahoo FinanceALEC
      Earnings Estimates Rising for Alector (ALEC): Will It Gain?
      Nov 11Yahoo FinanceALEC
      Alector: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceALEC
      Alector Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 5Yahoo FinanceALEC
      What Alector Shareholders Got Right

      If you only glanced at Alector’s headline figures, the story might look confusing. Total revenue was US$7.874 million in Q2 2025 and US$3.32 million in Q2 2026, while the firm’s net loss narrowed from US$30.524 million to US$22.99 million. For Alector shareholders, the return over the past year was 49.3%, including dividends. If you had been weighing a position back in November 2025, what exactly were you being paid to believe about this business? The easy part of this move is behind Alector...

      Nov 3Yahoo FinanceALEC
      Will Alector (ALEC) Report Negative Q3 Earnings? What You Should Know
      Oct 29Yahoo FinanceALEC
      Alector: Maintaining 'Hold' ABC Platform Transition And GCase Partnership With Roche

      Alector holds steady despite trial failures, pivoting to ABC platform, and Roche deal extends cash to 2029. Read why ALEC stock is a Hold.

      Oct 19Seeking AlphaALEC
      Alector Announces $75 Million Common Stock Offering

      Detailed price information for Alector Inc (ALEC-Q) from The Globe and Mail including charting and trades.

      Oct 17The Globe and MailALEC
      Alector stock surges 13% on premium-priced equity offering
      Oct 16Yahoo FinanceALEC
      Why is Alector stock surging today?
      Oct 16Investing.comALEC
      Alector stock rises after pricing equity offering (ALEC:NASDAQ)

      Alector (ALEC) stock jumps after a $75M equity offering priced at $2.05/share. Read more here.

      Oct 16Seeking AlphaALEC
      Update: Alector Prices $75 Million Stock Offering
      Oct 16Yahoo FinanceALEC
      Alector Prices $75 Million Stock Offering
      Oct 16Yahoo FinanceALEC
      Alector Announces Pricing of Underwritten Offering
      Oct 16Yahoo FinanceALEC
      Alector (ALEC) Stock Fair Value Rises After Genentech Deal Draws Split Analyst Views
      Oct 16Yahoo FinanceALEC
      Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments - Slideshow (NASDAQ:ALEC) 2026-10-15
      Oct 15Seeking AlphaALEC
      Alector Reprices Employee Stock Options to Boost Retention

      Detailed price information for Alector Inc (ALEC-Q) from The Globe and Mail including charting and trades.

      Oct 15The Globe and MailALEC
      H.C. Wainwright raises Alector stock price target on platform progress
      Oct 15Investing.comALEC
      Alector Maps Brain-Delivery Pipeline for Alzheimer’s, Parkinson’s Therapies
      Oct 13Yahoo FinanceALEC
      Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
      Oct 10Yahoo FinanceALECGEHCVTRSBHVN
      Mizuho Securities Keeps Their Hold Rating on Alector (ALEC)

      Detailed price information for Alector Inc (ALEC-Q) from The Globe and Mail including charting and trades.

      Oct 8The Globe and MailALEC
      Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
      Oct 7Yahoo FinanceALEC
      Analysts Are Bullish on Top Healthcare Stocks: Alector (ALEC), McKesson (MCK)

      Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailALEC
      Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Vaxcyte (PCVX) and CVS Health (CVS)

      Detailed price information for CVS Corp (CVS-N) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailALEC
      Morgan Stanley Remains a Sell on Alector (ALEC)

      Detailed price information for Alector Inc (ALEC-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailALEC
      Morgan Stanley raises Alector stock price target on milestone credit
      Oct 6Investing.comALEC
      Mizuho reiterates Alector stock rating at Neutral on Roche deal
      Oct 6Investing.comALEC
      Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal

      Alector’s approach combines an engineered GCase with the biotech’s blood-brain barrier delivery platform.

      Oct 6Yahoo FinanceALEC
      Update: Alector Shares Rise After Licensing AL050 Program to Roche's Genentech
      Oct 5Yahoo FinanceALEC
      Biotech Junior Gains 21% as US$100M Upfront Pharma Deal Extends Cash Runway

      Real-time index price for TSX Venture Composite Index (JX), along with buy or sell indicators, analysis, charts, historical performance, news and more

      Oct 5The Globe and MailALEC
      Why is Alector stock surging today?
      Oct 5Investing.comALEC
      Alector Signs $1.27 Billion Genentech License Agreement for Parkinson’s Disease Program

      Alector will receive $100 million upfront and could earn up to $1. 17 billion in additional milestones while Genentech assumes responsibility for developing and commercializing AL050 globally.

      Oct 5Yahoo FinanceALEC
      Alector surges on licensing agreement with Genentech ( (ALEC:NASDAQ)

      Alector stock jumps 22% after Genentech/Roche licenses AL050 for Parkinson’s. Read more here.

      Oct 5Seeking AlphaALEC
      Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug

      The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the FDA endorsed broader use of a Lilly medicine.

      Oct 5Yahoo FinanceALEC
      Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
      Oct 5ReutersALEC
      Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
      Oct 5Yahoo FinanceALEC
      12 Health Care Stocks Moving In Monday's Pre-Market Session
      Oct 5BenzingaALEC
      Alector at Morgan Stanley conference: reset centers on brain delivery
      Sep 15Investing.comALECMS
      Alector at Cantor healthcare conference: brain-shuttle pipeline in focus
      Sep 10Investing.comALEC
      Alector’s Grace Wong-Sarad sells $24,665 in shares
      Sep 4Investing.comALEC
      Alector CEO Arnon Rosenthal sells $193,473 in stock
      Sep 4Investing.comALEC
      Alector CFO Neil Berkley sells $77,948 of ALEC shares
      Sep 4Investing.comALEC
      Alector to Participate in Upcoming Healthcare Conferences

      SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 (New York, New York)Thursday, September 10, 2026, at 2:10 p.m. ET, fireside chat Morgan Stanley 24th Annual Global Healthcare Conference (N

      Sep 3Yahoo FinanceALEC
      12 Health Care Stocks Moving In Tuesday's After-Market Session
      Aug 25BenzingaAKANALECMRKRNRSNSYREVVOS

      This is the newest page. Registered accounts read further back.